ID   B16-F10.9
AC   CVCL_E3VQ
SY   F10.9; Clone F10.9
DR   CancerTools; 160882
DR   Ximbio; 160882
RX   PubMed=1906054;
RX   PubMed=2639904;
CC   Characteristics: Highly metastatic. Expresses low level of MHC class I antigens (PubMed=1906054; PubMed=2639904).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0159 ! B16-F10
SX   Male
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=1906054; DOI=10.1002/ijc.2910470713;
RA   Porgador A., Brenner B., Vadai E., Feldman M., Eisenbach L.;
RT   "Immunization by gamma-IFN-treated B16-F10.9 melanoma cells protects
RT   against metastatic spread of the parental tumor.";
RL   Int. J. Cancer Suppl. 6:54-60(1991).
//
RX   PubMed=2639904; DOI=10.1111/j.1744-313x.1989.tb00475.x;
RA   Porgador A., Feldman M., Eisenbach L.;
RT   "H-2Kb transfection of B16 melanoma cells results in reduced
RT   tumourigenicity and metastatic competence.";
RL   J. Immunogenet. 16:291-303(1989).
//